CompanyGraph
Shenzhen Neptunus Bioengineering Co., Ltd.
000078 · SZSE · China
neptunusbio.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $3.74B, above the global median of $520.53M
- FinancialsAltman Z-Score 0.95: distress zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.34BCNY643.82M · vs all stocks (USD)
Revenue (TTM)
25.24BCNY3.74B · vs all stocks (USD)
Profit Margin
-2.27%Beta
0.0130xvs all stocks
52-Week Change
-39.56%vs all stocks
Market Capitalization
4.34BCNY643.82M · vs all stocks (USD)
Enterprise Value
13.27BCNY1.97B · vs all stocks (USD)
Forward P/E
5.22xPrice to Sales (TTM)
0.1741xPrice to Book (MRQ)
3.54xEnterprise to Revenue
0.5260xEnterprise to EBITDA
30.54xGross Margin
9.28%Profit Margin
-2.27%Operating Margin
3.05%Return on Assets (TTM)
0.68%Return on Equity (TTM)
-22.83%Revenue (TTM)
25.24BCNY3.74B · vs all stocks (USD)
Revenue per Share (TTM)
9.59CNYUpdated Aug 18, 2026Quarterly Revenue Growth
-19.40%Gross Profit (TTM)
2.34BCNY346.92M · vs all stocks (USD)
EBITDA (TTM)
810.21MCNY120.15M · vs all stocks (USD)
Net Income (TTM)
-572.28MCNY-84.87M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-38.90%Operating Cash Flow (TTM)
83.68MCNY12.41M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-466.78MCNY-69.22M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
949.40MCNYFY2025 · Dec 31, 2025Revenue
26.67BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
24.21BCNYFY2025 · Dec 31, 2025Gross Profit
2.46BCNYFY2025 · Dec 31, 2025Operating Income
569.20MCNY84.41M · vs all stocks (USD)
Pre-tax Income
-499.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
53.26MCNYFY2025 · Dec 31, 2025Net Income
-552.56MCNYFY2025 · Dec 31, 2025EBIT
125.46MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
810.21MCNYFY2025 · Dec 31, 2025Research & Development
33.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
768.16MCNYFY2025 · Dec 31, 2025Other Operating Expenses
77.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
43.71MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
624.77MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2140CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2140CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
2.63BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
2.63BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-552.56MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-10.50MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
2.83BCNYFY2025 · Dec 31, 2025Free Cash Flow
2.73BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.45BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-552.56MCNYFY2025 · Dec 31, 2025Other Non-cash Items
637.08MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
2.49BCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
257.16MCNYFY2025 · Dec 31, 2025Capital Expenditures
-96.85MCNYFY2025 · Dec 31, 2025Net Acquisitions
30.54MCNYFY2025 · Dec 31, 2025Purchase of Investments
-734.16MCNYFY2025 · Dec 31, 2025Sale of Investments
836.54MCNYFY2025 · Dec 31, 2025Other Investing Activity
3.60MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
39.66MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
11.30BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-10.74BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-513.15MCNYFY2025 · Dec 31, 2025Other Financing Charges
120.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
167.90MCNYFY2025 · Dec 31, 2025Shares Outstanding
2.63BSharesUpdated Aug 18, 2026Float Shares
1.40BSharesUpdated Aug 18, 2026% Held by Insiders
47.61%vs all stocks
% Held by Institutions
0.34%vs all stocks
Total Cash (MRQ)
3.59BCNY532.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.36CNYUpdated Aug 18, 2026Total Debt (MRQ)
11.55BCNY1.71B · vs all stocks (USD)
Total Debt to Equity (MRQ)
5.36xCurrent Ratio (MRQ)
1.00xBook Value per Share (MRQ)
0.4720CNYUpdated Aug 18, 2026Total Assets
26.33BCNY3.91B · vs all stocks (USD)
Total Current Assets
23.74BCNYFY2025 · Dec 31, 2025Total Liabilities
24.16BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.60BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
454.67MCNYFY2025 · Dec 31, 2025Total Current Liabilities
23.70BCNYFY2025 · Dec 31, 2025Cash
1.45BCNYFY2025 · Dec 31, 2025Cash Equivalents
1.53BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.98BCNYFY2025 · Dec 31, 2025Other Short-term Investments
116.80MCNYFY2025 · Dec 31, 2025Accounts Receivable
13.20BCNYFY2025 · Dec 31, 2025Inventory
3.20BCNYFY2025 · Dec 31, 2025Accounts Payable
8.47BCNYFY2025 · Dec 31, 2025Short-term Debt
11.26BCNYFY2025 · Dec 31, 2025Other Current Liabilities
405.77MCNYFY2025 · Dec 31, 2025Long-term Debt
435.23MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
499.53KCNYFY2025 · Dec 31, 2025Common Stock (Book)
2.63BCNYFY2025 · Dec 31, 2025Retained Earnings
-3.49BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.18BCNY322.78M · vs all stocks (USD)
52-Week Low
1.27CNYUpdated Aug 18, 202652-Week High
5.70CNYUpdated Aug 18, 202652-Week Change
-39.56%vs all stocks
Beta
0.0130xvs all stocks
50-Day MA
1.66CNYUpdated Aug 18, 2026200-Day MA
2.90CNYUpdated Aug 18, 2026Avg 10-Day Volume
94.09MSharesUpdated Aug 18, 2026Avg 30-Day Volume
151.11MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
-0.2200CNYUpdated Aug 18, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 0.95: distress zoneCritical
Altman Z-Score: 0.95
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $3.74B, above the global median of $520.53MNotable
Revenue (USD): 3,742,686,308.147Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
476830
Tier 1ProductionApproval-Gated PipelineRule
Lionco Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
MiMedx Group, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tactile Systems Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ironwood Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhongzhu Healthcare Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lanzhou Foci Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Guosheng Shian Technology Co., Ltd.
4 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownWithin or Near the Altman Distress Zone
Daaz Bara Lestari Tbk.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown
Beijing VRV Software Corp.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And Drawdown